Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8720624 | Best Practice & Research Clinical Gastroenterology | 2018 | 5 Pages |
Abstract
Pubmed and Scopus databases were systematically searched through November 2017 to identify meta-analyses of RCTs that have investigated potential harms of biological agents (adalimumab, golimumab, infliximab, and vedolizumab) in patients with UC. Ten eligible meta-analyses were included. The body of available evidence supports the safety of biologic therapies in UC. Further research is needed to clarify the risk of any infection with biologics, for elderly and high-risk groups, for longer-term effects, and for head-to-head comparisons between the different biologics.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Stefanos Bonovas, Katerina Pantavou, Despo Evripidou, Anan Judina Bastiampillai, Georgios K. Nikolopoulos, Laurent Peyrin-Biroulet, Silvio Danese,